Provention Bio, Inc. PRVB
Set alert
24.98 0.00 0.00%
At close · Apr 26
24.98 Day range 25.00
52-week range unavailable
- Open
- 24.99
- Prev close
- 24.98
- Mkt cap
- 2.38B
- Vol
- 9.12M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 24.98
- High
- 25.00
- Forward P/E
- -192.15
- Beta
- 2.46
- Short ratio
- 1.53
- Inst. own
- 53.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 4, 2023
- 50-d avg
- 19.10
- 200-d avg
- 10.15
- 1y target
- 23.50
2Y chart
Events in this range
- Nov 4, 2021Earnings: —; estimate -0.47; surprise —%
- Feb 24, 2022Earnings: —; estimate -0.44; surprise —%
- May 5, 2022Earnings: —; estimate -0.45; surprise —%
- Aug 4, 2022Earnings: —; estimate -0.49; surprise —%
- Nov 3, 2022Earnings: —; estimate -0.46; surprise —%
- Nov 21, 2022Rating: SVB Leerink · — → Outperform
- Feb 15, 2023Rating: HC Wainwright & Co. · — → Buy
- Mar 13, 2023Rating: Chardan Capital · — → Buy
- Mar 14, 2023Downgrade: Jefferies · Buy → Hold
- Mar 14, 2023Downgrade: SMBC Nikko · Outperform → Neutral
- Mar 15, 2023Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (63)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Mar 31, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 13, 2023 | 3 years ago |
| RSI: Overbought | Mar 13, 2023 | 3 years ago |
| RSI: Oversold | Mar 10, 2023 | 3 years ago |
| RSI: Oversold | Mar 8, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 22, 2023 | 3 years ago |
| SMA: Bearish | Feb 21, 2023 | 3 years ago |
| SMA: Bullish | Feb 9, 2023 | 3 years ago |
| SMA: Bearish | Feb 8, 2023 | 3 years ago |
| SMA: Bullish | Feb 7, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 3, 2023 | 3 years ago |
| SMA: Bearish | Jan 18, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 18, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 17, 2023 | 3 years ago |
| SMA: Bullish | Jan 10, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 4, 2023 | 3 years ago |
| MACD: Buy Signal | Dec 29, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 5, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 23, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 21, 2022 | 3 years ago |
| RSI: Overbought | Nov 14, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 10, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 9, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 3, 2022 | 3 years ago |
| RSI: Overbought | Nov 3, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 25, 2022 | 4 years ago |
| SMA: Bullish | Oct 6, 2022 | 4 years ago |
| RSI: Overbought | Oct 6, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 5, 2022 | 4 years ago |
| SMA: Bullish | Oct 4, 2022 | 4 years ago |
| SMA: Bearish | Sep 29, 2022 | 4 years ago |
| SMA: Bullish | Sep 28, 2022 | 4 years ago |
| SMA: Bearish | Sep 21, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 20, 2022 | 4 years ago |
| SMA: Bearish | Sep 16, 2022 | 4 years ago |
| SMA: Bullish | Sep 15, 2022 | 4 years ago |
| SMA: Bearish | Sep 13, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 9, 2022 | 4 years ago |
| SMA: Bullish | Sep 1, 2022 | 4 years ago |
| SMA: Bearish | Aug 30, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 23, 2022 | 4 years ago |
| RSI: Overbought | Aug 10, 2022 | 4 years ago |
| SMA: Bullish | Aug 4, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 4, 2022 | 4 years ago |
| SMA: Bearish | Jul 22, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 22, 2022 | 4 years ago |
| SMA: Bullish | Jul 7, 2022 | 4 years ago |
| MACD: Buy Signal | May 17, 2022 | 4 years ago |
| RSI: Oversold | May 6, 2022 | 4 years ago |
| RSI: Oversold | Apr 26, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 31, 2022 | 4 years ago |
| RSI: Overbought | Mar 18, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 15, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 1, 2022 | 4 years ago |
| SMA: Bullish | Feb 7, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 31, 2022 | 4 years ago |
| RSI: Oversold | Jan 18, 2022 | 4 years ago |
| RSI: Oversold | Jan 12, 2022 | 4 years ago |
Key statistics
- Market cap
- 2.38B
- Enterprise value
- 2.17B
- Trailing P/E
- 0.00
- Forward P/E
- -192.15
- PEG ratio
- 0.00
- Price / sales
- 184.21
- Price / book
- 17.97
- EPS (TTM)
- -1.52
- Beta
- 2.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 12.89M
- Revenue growth
- 1408.10%
- Free cash flow
- 2.87M
- Total cash
- 165.00M
- Total debt
- 24.06M
- Return on equity
- -97.66%
- Shares outstanding
- 91.10M
- Short % of float
- 7.58%
- 50-day average
- 19.10
- 200-day average
- 10.15
Analyst view
Consensus: buy
Buy
Price target (mean) 23.50 -5.9% downside
Now 24.98
- Target (low)
- 19.00
- Target (mean)
- 23.50
- Target (high)
- 25.00
Next earnings
May 4, 2023
Expected May 4, 2023. Consensus EPS estimate -1.54.
Financials — quick view
PRVB Revenue — quarterly 10.81M
PRVB Net income — quarterly -33.28M
PRVB EPS — quarterly -0.38
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 4, 2023 | Mar 1, 2023 | -0.97 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | -0.46 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.49 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.45 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | -0.44 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.47 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 15, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 14, 2023 | SMBC Nikko | down | Outperform | Neutral |
| Mar 14, 2023 | Jefferies | down | Buy | Hold |
| Mar 13, 2023 | Chardan Capital | main | — | Buy |
| Feb 15, 2023 | HC Wainwright & Co. | main | — | Buy |
| Nov 21, 2022 | SVB Leerink | main | — | Outperform |
About Provention Bio, Inc.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- proventionbio.com
News
- Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.
- The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
- PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
- Why Provention Bio Stock Skyrocketed 256% This Week
- Earnings Scheduled For March 16, 2023
- Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB
- This biopharma stock jumped over 250% on Monday: what happened?
- Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
- Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Your note
Sign in to keep a note on PRVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLUESTONE JEFFREY PH.D. | Director | Conversion of Exercise of derivative security | Apr 9, 2020 | 0 |
| CATLIN AVERY W | Director | Stock Gift | Apr 12, 2023 | 20,000 |
| DIGIANDOMENICO ANTHONY | Director | Purchase | Sep 29, 2019 | 178,712 |
| DRECHSLER ANDREW T | Chief Financial Officer | Purchase | Sep 1, 2020 | 20,000 |
| HOITT JASON | Officer | Sale | Feb 9, 2023 | 0 |
| LEON FRANCISCO | Officer | Stock Gift | Apr 12, 2023 | 146,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | 15.70% | 14,879,023 | 371.68M | Dec 30, 2022 |
| Blackrock Inc. | 5.89% | 5,579,604 | 139.38M | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 4.37% | 4,142,744 | 103.49M | Dec 30, 2022 |
| Adage Capital Partners GP L.L.C. | 2.66% | 2,519,257 | 62.93M | Dec 30, 2022 |
| State Street Corporation | 1.64% | 1,558,238 | 38.92M | Dec 30, 2022 |
| Geode Capital Management, LLC | 1.39% | 1,322,189 | 33.03M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.69% | 2,553,871 | 63.80M | Dec 30, 2022 |
| iShares Russell 2000 ETF | 1.46% | 1,380,809 | 34.49M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 1.11% | 1,052,768 | 26.30M | Dec 30, 2022 |
| iShares NASDAQ Biotechnology ETF | 0.67% | 635,394 | 15.87M | Feb 27, 2023 |
| Fidelity Small Cap Index Fund | 0.55% | 521,048 | 13.02M | Jan 30, 2023 |
| Principal Capital Appreciation Fund | 0.49% | 460,658 | 11.51M | Jan 30, 2023 |